Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Pharvaris Netherlands BV

Home Clinical Trial Sponsors and OrganizationsPharvaris Netherlands BV

Pharvaris Netherlands BV

ACTIVE

NetherlandsSubsidiary

Part of Pharvaris NV

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

18

12 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

13

72.2%

Phase 2

1

5.6%

Trial Status Distribution

Active, not recruiting

12

66.7%

Completed

5

27.8%

Recruiting

1

5.6%

Clinical Trials

Trials sponsored by this organization (18)

A blinded, placebo-controlled and randomized phase 2 study to test different doses of oral PHA-022121 for prophylaxis of angioedema attacks in patients with hereditary angioedema (HAE).

Jan 202330 participants

A blinded, placebo-controlled and randomized phase 2 study to test different doses of oral PHA-022121 for prophylaxis of angioedema attacks in patients with hereditary angioedema (HAE).

Active, not recruiting

Dec 202230 participants

An extension phase 2/3 study to test the safety of long term administration of oral PHA-022121 for acute treatment of angioedema attacks in patients with hereditary angioedema

Active, not recruiting

Jun 202272 participants

An extension phase 2/3 study to test the safety of long term administration of oral PHA-022121 for acute treatment of angioedema attacks in patients with hereditary angioedema

Active, not recruiting

May 202272 participants

A blinded, placebo-controlled and randomized phase 2 study to test different doses of oral PHA-022121 for prophylaxis of angioedema attacks in patients with hereditary angioedema (HAE).

Active, not recruiting

Dec 202130 participants

A blinded, placebo-controlled and randomized phase 2 study to test different doses of oral PHA-022121 for prophylaxis of angioedema attacks in patients with hereditary angioedema (HAE).

Active, not recruiting

Nov 202130 participants

A blinded, placebo-controlled and randomized phase 2 study to test different doses of oral PHA-022121 for acute treatment of angioedema attacks in patients with hereditary angioedema (HAE).

Active, not recruiting

Mar 202172 participants

A blinded, placebo-controlled and randomized phase 2 study to test different doses of oral PHA-022121 for acute treatment of angioedema attacks in patients with hereditary angioedema (HAE).

Active, not recruiting

Feb 202172 participants

Page 1 of 3

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials18
Approvals
News

Back to Organizations